Cholestech gets US thumbs-up for CRP test:
This article was originally published in Clinica
The US FDA has given Cholestech 510(k) market clearance to add a high sensitivity C-reactive protein (hs-CRP) blood test to the menu of assays run on its LDX tabletop analyser. The test, the first immunoassay developed for use on the analyser, can help doctors assess arterial inflammation and risk of heart disease. Laboratories will be able to use the test on the LDX system following the completion of a simple software upgrade, says the Hayward, California firm. Cholesterol and liver enzyme tests are already available for use on the analyser.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.